Link between sterile inflammation and cardiovascular diseases: Focus on cGAS-STING pathway in the pathogenesis and therapeutic prospect

Sterile inflammation characterized by unresolved chronic inflammation is well established to promote the progression of multiple autoimmune diseases, metabolic disorders, neurodegenerative diseases, and cardiovascular diseases, collectively termed as sterile inflammatory diseases. In recent years, s...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in cardiovascular medicine Vol. 9; p. 965726
Main Authors Du, Yao, Zhang, Hui, Nie, Xiaoyan, Qi, Yajun, Shi, Shi, Han, Yingying, Zhou, Wenchen, He, Chaoyong, Wang, Lintao
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 22.08.2022
Subjects
cardiovascular diseases
Cardiovascular Medicine
cGAS
inflammation
STING
therapy
Online AccessGet full text

Cover

More Information
Summary:Sterile inflammation characterized by unresolved chronic inflammation is well established to promote the progression of multiple autoimmune diseases, metabolic disorders, neurodegenerative diseases, and cardiovascular diseases, collectively termed as sterile inflammatory diseases. In recent years, substantial evidence has revealed that the inflammatory response is closely related to cardiovascular diseases. Cyclic guanosine monophosphate–adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING) pathway which is activated by cytoplasmic DNA promotes the activation of interferon regulatory factor 3 (IRF3) or nuclear factor-κB (NF-κB), thus leading to upregulation of the levels of inflammatory factors and interferons (IFNs). Therefore, studying the role of inflammation caused by cGAS-STING pathway in cardiovascular diseases could provide a new therapeutic target for cardiovascular diseases. This review focuses on that cGAS-STING-mediated inflammatory response in the progression of cardiovascular diseases and the prospects of cGAS or STING inhibitors for treatment of cardiovascular diseases.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
This article was submitted to Cardiovascular Therapeutics, a section of the journal Frontiers in Cardiovascular Medicine
These authors have contributed equally to this work
Reviewed by: Yifan Lu, Temple University, United States; Herman Sintim, Purdue University, United States; Yu Cui, Qingdao University, China
Edited by: Xiaofeng Yang, Temple University, United States
ISSN:2297-055X
2297-055X
DOI:10.3389/fcvm.2022.965726